Patent: 5,549,892
✉ Email this page to a colleague
Summary for Patent: 5,549,892
| Title: | Enhanced in vivo uptake of glucocerebrosidase |
| Abstract: | A pharmaceutical composition comprising remodelled recombinant glucocerebrosidase (GCR) is described that provides a therapeutic effect at doses that are lower then those required using remodelled naturally occurring GCR. A method of treating patients with Gaucher\'s disease using remodelled recombinant GCR is also provided. In vivo uptake of exogenous molecules can be determined by extracting a mixture of cells from a subject, enriching the target cells in vitro, lysing the cells and determining the amount of exogenous molecules. |
| Inventor(s): | Friedman; BethAnn (Arlington, MA), Hayes; Michael (Acton, MA) |
| Assignee: | Genzyme Corporation (Cambridge, MA) |
| Application Number: | 08/080,855 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,549,892
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | May 23, 1994 | ⤷ Sign Up | 2013-08-27 |
| Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | September 22, 1999 | ⤷ Sign Up | 2013-08-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
